Alzheimer's gold rush in­spires $565M deal be­tween Chi­nese phar­ma pow­er­house and lit­tle Ger­man biotech

The bal­loon­ing con­tro­ver­sy around Bio­gen and its Alzheimer’s drug isn’t de­ter­ring oth­ers from the gold rush — and the search is glob­al.

Chi­na’s Sim­cere is li­cens­ing re­gion­al rights to a Phase IIb an­ti-amy­loid drug from Ger­man biotech Vivory­on Ther­a­peu­tics and tak­ing the lead on clin­i­cal de­vel­op­ment lo­cal­ly. All told, the pact is val­ued at up to $565 mil­lion, in­clud­ing an undis­closed up­front pay­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.